JP2010537958A5 - - Google Patents

Info

Publication number

JP2010537958A5

JP2010537958A5 JP2010522397A JP2010522397A JP2010537958A5 JP 2010537958 A5 JP2010537958 A5 JP 2010537958A5 JP 2010522397 A JP2010522397 A JP 2010522397A JP 2010522397 A JP2010522397 A JP 2010522397A JP 2010537958 A5 JP2010537958 A5 JP 2010537958A5

Authority

JP

Japan

Prior art keywords

oligomer

oligomer according

nucleotide analogues

nucleotide

nucleobase

Prior art date

2008-08-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003729 nucleotide group Chemical group 0.000 claims 23
• 239000002773 nucleotide Substances 0.000 claims 7
• 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims 6
• 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims 5
• 102100034343 Integrase Human genes 0.000 claims 4
• 101710203526 Integrase Proteins 0.000 claims 4
• 108020004707 nucleic acids Proteins 0.000 claims 4
• 150000007523 nucleic acids Chemical class 0.000 claims 4
• 102000039446 nucleic acids Human genes 0.000 claims 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
• 108020004394 Complementary RNA Proteins 0.000 claims 2
• 239000003184 complementary RNA Substances 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 208000027866 inflammatory disease Diseases 0.000 claims 2
• 108020004999 messenger RNA Proteins 0.000 claims 2
• 208000030159 metabolic disease Diseases 0.000 claims 2
• PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 102000047030 human FABP4 Human genes 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000001483 mobilizing effect Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1